KYMR
Kymera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$108.07
+3.14%Year over year
Reported trailing growth
- Revenue
- +134.8%
- EBITDA
- -9.1%
- EBIT
- -12.3%
- EPS
- +6.3%
- Free cash flow
- +5.9%
- Operating cash flow
- +5.7%
Forward estimates
Based on analyst estimates
- Revenue
- -68.6%
- EBITDA
- -73.0%
- EPS
- -60.4%
Three-year CAGR
- Revenue
- -5.8%
- EBITDA
- -40.2%
- EBIT
- -33.5%
- Net income
- -39.1%
- EPS
- -23.8%
- Free cash flow
- -13.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026